Beijing Xuanwu Hospital

METiS TechBio's AI-Designed Drug MTS-004 Becomes First in China to Complete Phase III Trial for Pseudobulbar Affect

- MTS-004 has become China's first AI-enabled formulation drug candidate to successfully complete Phase III clinical trials, marking a significant milestone in AI-driven pharmaceutical development. - The drug targets Pseudobulbar Affect (PBA), a neurological condition causing involuntary laughing and crying episodes, representing the first and only therapy for this indication to reach Phase III in China. - Using METiS TechBio's proprietary AiTEM platform, the drug development timeline was compressed from the typical industry average to just 38 months from concept to Phase III completion. - The Phase III trial demonstrated statistically significant improvements in PBA symptoms, with therapeutic benefits observable as early as week 2 and sustained improvement throughout the 12-week treatment period.